Johnson & Johnson (NYSE:JNJ) has received an average rating of “Hold” from the twenty-two research firms that are covering the firm, Marketbeat reports. Four research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation, eight have given a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among analysts that have covered the stock in the last year is $146.02.
Several equities research analysts recently issued reports on the stock. Wells Fargo & Co reiterated an “outperform” rating and issued a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a research note on Friday, January 12th. Vetr upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price for the company in a research note on Thursday, January 11th. Credit Suisse Group set a $154.00 target price on shares of Johnson & Johnson and gave the company a “hold” rating in a research note on Monday, January 22nd. Royal Bank of Canada reiterated a “buy” rating on shares of Johnson & Johnson in a research note on Tuesday, January 9th. Finally, Stifel Nicolaus raised their target price on shares of Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research note on Wednesday, January 24th.
In other Johnson & Johnson news, VP Paulus Stoffels sold 155,342 shares of the stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $129.86, for a total value of $20,172,712.12. Following the transaction, the vice president now directly owns 357,906 shares of the company’s stock, valued at approximately $46,477,673.16. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 0.19% of the stock is owned by corporate insiders.
A number of institutional investors have recently added to or reduced their stakes in JNJ. Goodman Financial Corp bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $104,000. Harding Loevner LP bought a new position in shares of Johnson & Johnson during the second quarter worth approximately $106,000. Stelac Advisory Services LLC bought a new position in shares of Johnson & Johnson during the fourth quarter worth approximately $108,000. Mitsubishi UFJ Securities Holdings Co. Ltd. increased its holdings in shares of Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock worth $115,000 after purchasing an additional 200 shares during the period. Finally, IHT Wealth Management LLC increased its holdings in shares of Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock worth $122,000 after purchasing an additional 3,467 shares during the period. 66.38% of the stock is currently owned by hedge funds and other institutional investors.
Johnson & Johnson (NYSE:JNJ) opened at $133.80 on Friday. Johnson & Johnson has a one year low of $120.95 and a one year high of $148.32. The company has a debt-to-equity ratio of 0.51, a quick ratio of 1.12 and a current ratio of 1.41. The company has a market cap of $358,972.31, a PE ratio of 343.08, a PEG ratio of 2.19 and a beta of 0.77.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, January 23rd. The company reported $1.74 EPS for the quarter, topping the Zacks’ consensus estimate of $1.72 by $0.02. Johnson & Johnson had a net margin of 1.70% and a return on equity of 29.00%. The company had revenue of $20.20 billion during the quarter, compared to the consensus estimate of $20.08 billion. During the same period in the prior year, the business posted $1.58 EPS. The company’s quarterly revenue was up 11.5% on a year-over-year basis. research analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current year.
The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Shareholders of record on Tuesday, February 27th will be issued a $0.84 dividend. The ex-dividend date of this dividend is Monday, February 26th. This represents a $3.36 annualized dividend and a yield of 2.51%. Johnson & Johnson’s dividend payout ratio is currently 861.54%.
TRADEMARK VIOLATION NOTICE: “Johnson & Johnson (JNJ) Given Average Recommendation of “Hold” by Brokerages” was originally reported by Enterprise Leader and is the sole property of of Enterprise Leader. If you are reading this article on another site, it was illegally copied and republished in violation of US and international copyright and trademark law. The correct version of this article can be viewed at https://theenterpriseleader.com/2018/04/02/johnson-johnson-jnj-given-average-recommendation-of-hold-by-brokerages.html.
Johnson & Johnson Company Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.